JAN 17, 2021 8:20 AM PST

A Single Dose Nanoparticle Vaccine for COVID-19

WRITTEN BY: Heba El Wassef

In the race for finding the right vaccine for the COVID-19 pandemic, a new vaccine candidate emerged. Researchers at Stanford University are trying to develop a new vaccine that could be more affordable and easy to reach low and middle-income countries.

In a paper published at ACS Central Science, the new vaccine uses ferritin nanoparticles as an adjuvant to increase the immunogenic response towards the vaccine. Ferritin nanoparticles based vaccines have been proven effective in other clinical trials. 

Other vaccine candidates use mRNA vaccines as Pfizer and Moderna vaccines, live-attenuated vaccines, or recombinant viral vaccines. There are some issues with the other vaccine candidates as the need for freezing temperatures for storage as with mRNA vaccines or the risk of side effects as the vaccines using attenuated or recombinant viruses. The Stanford nanoparticle vaccine is a subunit vaccine that uses a part of the virus "spike protein." Still, subunit vaccines usually have lower immunogenicity than the ones using a whole virus, and here comes the importance of using ferritin nanoparticles.

Ferritin nanoparticles act as adjuvants that help present antigens "spike proteins" in an aggregated way that will increase the immune response towards them while being cheaper and easier to manufacture and stored, which will help the low and middle-income countries.

“This is really early stage and there is still lots of work to be done,” said Abigail Powell, a former postdoctoral scholar in the Kim lab and lead author of the paper. “But we think it is a solid starting point for what could be a single-dose vaccine regimen that doesn’t rely on using a virus to generate protective antibodies following vaccination.”

The researchers used a pseudo-coronavirus for safety and tested the results of four different vaccine variations; nanoparticles with full spike protein, full spikes or partial spikes without nanoparticles, and nanoparticles with a shortened spikes containing just the part of the spike that binds to cells during infections. 

They tested the vaccine's effectiveness by measuring the levels of neutralizing antibodies produced, the antibodies that can stop the virus's infection. After a single dose, the two nanoparticles vaccines produced neutralizing antibody levels twice as high as the antibody levels produced in patients who had been infected with the coronavirus, and the shortened spike vaccine produced higher antibody levels than the rest.

Since the Stanford vaccine is still in its initial phase and other coronavirus vaccine candidates are rapidly reaching their final phases, it might be not needed for facing this ongoing coronavirus pandemic. Researchers are ready to change the research to use this vaccine against other coronaviruses as SARS-CoV-1, MERS, SARS-CoV-2, and any future coronaviruses that could arise. 

“Vaccines are one of the most profound achievements of biomedical research. They are an incredibly cost-effective way to protect people against disease and save lives,” said Kim. “This coronavirus vaccine is part of work we’re already doing – developing vaccines that are historically difficult or impossible to develop, like an HIV vaccine – and I’m glad that we’re in a situation where we could potentially bring something to bear if the world needs it.”

Sources: Stanford News, ACS Central Science, Youtube

About the Author
  • A master student in Biochemistry and Molecular biology with experience in Education and Research. I am passionate about scientific research and passing my knowledge to others to help them learn about the latest in science by teaching, writing and volunteering in scientific events.
You May Also Like
JUL 12, 2021
Cell & Molecular Biology
A Molecule From the Gut Microbiome May Fight Tumors
JUL 12, 2021
A Molecule From the Gut Microbiome May Fight Tumors
The more we learn abut the gut microbiome, the more it seems that the microorganisms in our gastrointestinal tracts can ...
AUG 10, 2021
Health & Medicine
Care Managers During COVID-19, A Vital Value-Add
AUG 10, 2021
Care Managers During COVID-19, A Vital Value-Add
At the beginning of 2020, fear was unleashed globally as the United States government announced a public health emergenc ...
AUG 13, 2021
Cancer
Ultrasound Triggers Immunotherapy to Destroy Tumors
AUG 13, 2021
Ultrasound Triggers Immunotherapy to Destroy Tumors
An immunotherapy engineered to be triggered by ultrasound beams significantly slows the growth of cancerous tumors in mi ...
SEP 02, 2021
Immunology
Will an Extra COVID Vaccine Shot Benefit People With Autoimmune Conditions?
SEP 02, 2021
Will an Extra COVID Vaccine Shot Benefit People With Autoimmune Conditions?
The global rollout of COVID-19 vaccines has helped save countless lives during the pandemic. Studies have shown that vac ...
SEP 06, 2021
Microbiology
Imbokodo Trial Shows HIV Vaccine Candidate Isn't Effective Enough
SEP 06, 2021
Imbokodo Trial Shows HIV Vaccine Candidate Isn't Effective Enough
HIV vaccines have remained elusive in part because the virus has a powerful ability to mutate, and there are so many str ...
OCT 19, 2021
Immunology
Reverse Vaccinations Tame the Immune System to Help Hemophilia Patients
OCT 19, 2021
Reverse Vaccinations Tame the Immune System to Help Hemophilia Patients
In patients with hemophilia A—a hereditary disorder where the blood cannot clot properly—their immune system ...
Loading Comments...